Adaptive Designs for Infectious Diseases Clinical Development Strategy

Posted by Esha Senchaudhuri

Dec 11, 2014 1:14:00 PM

 

A common framework for the clinical development of vaccines involves the study of several candidate compounds in Phase 1 followed by the selection of potential vaccine regimens for study in Phase 2 and Phase 3. In the attached presentation, Cytel Consulting’s Jim Bolognese compares traditional and adaptive Phase 1/Phase 2 studies for vaccines and infectious diseases, providing simulations results for both 2-stage and multi-stage adaptive designs. Jim also outlines a structure for a Hybrid Adaptive Study.

Jim_BIn both traditional and adaptive studies for infectious diseases, a study of early bacteriocidal activity(EBA) is followed by a serial sputum colony count (SSCC) study. The difference is that while traditional trials have a fixed sample size for all regiments, in an adaptive trial there is ‘adaptive allocation’ of trial participants into the most promising regimens. Adaptive vaccine trials can take a similar structure, with a short-term study evaluating the titers of immune response, followed by a longterm efficacy study. 

Jim also proposes the Hybrid Adaptive Study in which both the EBA and SSCC are tested in a single 2-part study, with adaptive allocation into promising regimens.

View Slides  


 

Related Items of Interest

Adaptive Clinical Trials: Your Questions Answered

To Adapt or Not to Adapt? 10 Simple Steps to Deciding Whether Your Next Trial Should be Adaptive

 

Topics: Infectious Diseases, Clinical Development Strategy, Adaptive Clinical Trials

The Cytel blog keeps you up to speed with the latest developments in biostatistics and clinical biometrics.  Sign up for updates direct to your inbox. You can unsubscribe at any time.

 

Posts by Topic

see all

Recent Posts